Brief: Bergenbio Says Bemcentinib Shows Promising Clinical Activity In Lung Cancer

Oncoinvent ASA

13/01/2021 07:23

Jan 13 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BEMCENTINIB IN COMBINATION WITH  PEMBROLIZUMAB IS WELL
TOLERATED
AND SHOWED PROMISING CLINICAL ACTIVITY IN RESISTANT LUNG CANCER

Source text for Eikon:  ID:nWkr4L1DCX 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))